Chemical structure | Name in the literature | Target | Mechanism in RCD | Activity | TNBC subtype | References |
---|---|---|---|---|---|---|
PTX | Microtubule inhibitor | Active mitotic catastrophe | MDA-MB-231 (IC50 = 5.78 μM) Hs578T (IC50 = 0.15 μM) | MSL | [199] | |
| JQ1 | BET inhibitor | Active mitotic catastrophe | MDA-MB-231 (50 nM) HCC70 (500 nM) HCC1143 (200 nM) | BL1 MSL | |
| SB218078 | Chk1 inhibitor | Active mitotic catastrophe | HCC1937 (IC50 > 10 μM) IGRBr-11 (IC50=8.56 μM) | BL1 UNS | [208] |
| Torin2 | mTOR and PIKKs inhibitor | Active mitotic catastrophe | HCC1806 (GR50 = 0.08 μM) HCC70 (GR50 = 0.02 μM) | BL2 | [214] |
| KX-01 | SRC and tubulin inhibitor | Active mitotic catastrophe | MDA-MB-231 (IC50 = 0.0446 ± 0.0009 μM) MDA-MB-468 (IC50 = 0.0613 ± 0.0017 μM) BT-549 (IC50 = 0.0467 ± 0.0019 μM) | BL1 M MSL | [215] |
| erastin@FA-exo | Ferroptosis inducer | Active ferroptosis | MDA-MB-231 (IC50 = 10 μM) | MSL | [248] |
As4O6 | Tetraarsenic hexoxide (As4O6) | STAT3 inhibitor | Active pyroptosis | Hs578T (IC50 > 10 μM) MDA-MB-231 (IC50 = 5 μM) | MSL | [258] |
| Cisplatin | Activation of MEG3/NLRP3/caspase-1/GSDMD Pathway | Active pyroptosis | MDA-MB-231 (IC50 = 9.952 nM) | MSL | [260] |
| AEB071 | PKCθ inhibitor | Active anoikis | MDA-231-Luc-D3H2LN (IC50 = 500 nM) | [268] | |
Synthesized flavonoid derivative GL-V9 | Glucose-6-phosphate dehydrogenase (G6PD)↓ Phospho-acetyl-CoA carboxylase (p-ACC) AMPK↑ | Active anoikis | MDA-MB-231 (IC50 = 20 μM) | MSL | [271] | |
Tubeimoside V (TBMS-V) | EGFR↑ ITGB1-FAK↑ | Active anoikis | MDA-MB-231 (IC50 = 2.5 μM) | MSL | [272] | |
| Disulfiram/copper (DSF/Cu) | Calpain and decomposing vimentin in a Cu-dependent manner↑ | Active anoikis | MDA-MB-231 (IC50 = 1 μM) Hs578T (IC50 = 1 μM) | MSL | [274] |
| Salinomycin | STAT3 inhibitor | Active anoikis | MDA-MB-231 (IC50 = 10 μM, 72 h) | MSL | [286] |
POL5551 | CXCR4 inhibitor | Active anoikis | MSL | [294] | ||
| AL10 | Sialyltransferase inhibitor | Active anoikis | MDA-MB-231 (IC50 = 10 μM) | MSL | [296] |
| Berberine (BBR) | Active anoikis | MDA-MB-231 (IC50 = 10 μM) | MSL | [276] | |
| HPW-RX40 | Integrin inhibitor | Active anoikis | MDA-MB-231 (IC50 = 15.2 μM) | MSL | [297] |
Archazolid A | V-ATPase inhibitor | Active and inhibit anoikis | MDA-MB-231 (10 nM) | MSL | [298] | |
| Narciclasine | Upregulate AMPK-ULK1 pathway | Active autophagy-dependent cell death and apoptosis | HCC‐1937 (IC50 = 0.25 μM) MDA-MB-231 (IC50 = 0.5 μM) BT-579 (IC50 = 2 μM) | BL1 M MSL | [305] |
| Compound 7C (3-bromo-N'-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives) | mTOR inhibitor | Active autophagy-dependent cell death and apoptosis | MDA-MB-231 (IC50 = 3.38 ± 1.01 μM) MDA-MB-468 (IC50 = 4.30 ± 1.82 μM) | BL1 MSL | [306] |
| Cantharidin | Beclin1 inhibitor | Inhibit autophagy-dependent cell death and active apoptosis | MDA-MB-231 (IC50 = 10 µg/ml) MDA-MB-468 (IC50 = 10 µg/ml) | BL1 MSL | [307] |
Eupalinolide G
Eupalinolide I
Eupalinolide J | F1012-2 | Active Akt and p38 pathway | Inhibit autophagy-dependent cell death and active apoptosis | MDA-MB-231 (IC50 = 6.76 ± 0.42 µg/ml) MDA-MB-468 (IC50 = 6.23 ± 0.32 µg/ml) | [308] | |
| Flubendazole | EVA1A activator | Active autophagy-dependent cell death and apoptosis | MDA-MB-231 (IC50 = 0.623 μM) MDA-MB-468 (IC50 = 0.728 μM) | BLC1 MSL | [310] |
| CSC-3436 | AMPK/mTOR pathway ↓ | Active autophagy-dependent cell death and apoptosis | MDA-MB-231 (IC50 = 205 ± 3.21 nm for 48 h, IC50 = 148 ± 2.31 nm for 72 h) | MSL | [313] |
| Jatamanvaltrate P | Cleavage of PARP and caspases ↑; Cell cycle-related Cyclin B1, Cyclin D1 and Cdc-2 ↓ | Active autophagy-dependent cell death and apoptosis | MDA-MB-231 (IC50 = 4.32 ± 1.34 µM) MDA-MB-468 (IC50 = 7.05 ± 2.51 µM) MDA-MB-453 (IC50 = 4.05 ± 0.18 µM) | BL1 MSL LAR | [314] |
| 1,4,5-Oxathiazinane-4,4-dioxide (OTD) | Active necroptosis and apoptosis | BT-20 (IC50 = 500 μM) MDA-MB-231 (IC50 = 200 μM) | MSL UNS | [315] | |
AEZS 126 | PI3K/AKT inhibitor | Active necroptosis and apoptosis | HCC1937 (IC50 = 3.2 μM) | BL1 | [318] | |
| Azobenzene combretastatin A4 (Azo-CA4) | Microtubule inhibitor | Active ferroptosis and apoptosis | MDA-MB-231 (IC50 = 1.02 mg/mL) | MSL | [331] |
| DMOCPTL | GPX4 inhibitor | Active ferroptosis and apoptosis | MDA-MB-231 (IC50 = 0.34 ± 0.13 μM) | MSL | [320] |